SCHEDULE 13G/A: Biotechnology Value Fund Group Discloses 9.99% Stake in 4D Molecular Therapeutics

A group of investment entities led by Biotechnology Value Fund, L.P. and Mark N. Lampert has disclosed a combined beneficial ownership of 9.99% in 4D Molecular Therapeutics, Inc. common stock as of March 31, 2025.

Summary

• Biotechnology Value Fund, L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in 4D Molecular Therapeutics, Inc.
• As of March 31, 2025, the aggregate beneficial ownership by BVF Partners L.P., BVF Inc., and Mark N. Lampert is 4,632,749 shares, representing 9.99% of the outstanding common stock.
• This percentage is calculated based on 46,302,407 shares outstanding as of February 26, 2025, plus 71,460 shares underlying certain Pre-Funded Warrants exercisable by the Reporting Persons.
• Individual entities within the group hold varying percentages: BVF holds 2,331,627 shares (5.0%), BVF2 holds 1,902,682 shares (4.1%), and Biotechnology Value Trading Fund OS LP holds 299,876 shares (0.6%).
• The group holds Pre-Funded Warrants for an aggregate of 5,775,000 shares, but a 'Pre-Funded Warrants Blocker' limits the current exercisable amount to 71,460 shares to prevent exceeding the 9.99% beneficial ownership threshold.
• The filing states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of beneficial ownership by a significant institutional investor group. While it doesn't contain operational or financial performance data, the maintenance of a substantial stake (9.99%) by a specialized biotechnology fund can be interpreted as a vote of confidence in the issuer, 4D Molecular Therapeutics, Inc.

Positives

• Significant institutional investment by a specialized biotechnology fund, potentially signaling confidence in 4D Molecular Therapeutics, Inc.
• The investment group maintains a stake just below the 10% threshold, which avoids certain additional reporting requirements.

Risks

• The 'Pre-Funded Warrants Blocker' mechanism indicates a limitation on immediate full exercise of warrants, which could affect the reporting persons' ability to increase their stake beyond the 9.99% threshold without further disclosures or changes.

Future Outlook

NA

Management Comments

• Mark N. Lampert, on behalf of the reporting persons, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates continued or significant interest from a specialized biotechnology investment fund in 4D Molecular Therapeutics, Inc., a company operating in the biotechnology sector. Such filings are common for institutional investors managing large portfolios and adjusting their stakes in public companies.

Comparison to Industry Standards

• The 9.99% beneficial ownership threshold is a common strategic level for institutional investors to maintain a significant stake without triggering certain activist investor reporting requirements (e.g., Schedule 13D, which implies intent to influence control).
• The use of 'Pre-Funded Warrants Blocker' is a standard mechanism employed by investors to manage their beneficial ownership percentages and comply with regulatory thresholds, particularly in situations where they hold convertible securities.

Related Party Transactions

• The document details the hierarchical relationship between the various reporting entities (e.g., BVF GP is the general partner of BVF, BVF GPH is the sole member of BVF GP and BVF2 GP, Partners is the investment manager, BVF Inc. is the general partner of Partners, and Mark N. Lampert is a director and officer of BVF Inc.), which defines how beneficial ownership is attributed across these related entities.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which could influence investor sentiment. The continued holding of a large stake by a specialized fund might be viewed positively.
• Management: Awareness of a large, stable institutional shareholder.
• Regulatory Authorities: Fulfills SEC disclosure requirements for significant beneficial ownership.

Key Dates

Keywords

4D Molecular Therapeutics, Biotechnology Value Fund, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, pre-funded warrants, biotechnology, investment fund, shareholding disclosure